Bendamustine
Metastatic Malignant Neoplasm in the Bone
M.D. Anderson Cancer CenterSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Metastatic Malignant Neoplasm in the Bone cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 National Cancer Institute (NCI) | Phase 3 | BB |
Cyclophosphamide Mayo Clinic | Phase 1/2 | B |
Pembrolizumab Mayo Clinic | Phase 1/2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 3 | B |
Epirubicin Mayo Clinic | Phase 1/2 | B |
View all 26 →
Same molecule, other indications
Bendamustine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →